year 14, Issue 2 (March - April 2020)
Iran J Med Microbiol 2020, 14(2): 154-161 |
Back to browse issues page
Farzaneh Mohammadzadeh rostami1 
, Bahram Nasr Nasr Esfahani1 , Ali Mohammad Ahadi2 , Saman Shalibeik 3
, Bahram Nasr Nasr Esfahani1 , Ali Mohammad Ahadi2 , Saman Shalibeik 3
1- Department of Bacteriology and Virology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2- Department of Genetics, Faculty of Science, University of Shahrekord, Shahrekord, Iran
3- Department of Microbiology, Faculty of biological Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran , saman.shalibeik@gmail.com
2- Department of Genetics, Faculty of Science, University of Shahrekord, Shahrekord, Iran
3- Department of Microbiology, Faculty of biological Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran , saman.shalibeik@gmail.com
Abstract: (6464 Views)
On December 31, 2019, pneumonia due to the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV) appeared to Wuhan, China, and COVID-19 is an infectious disease caused by SARS. CoV-2. SARS-CoV-2 is a new strain of coronavirus that has not been previously identified in humans. Until April 18, 2020, 2275783 were confirmed and 156104 deaths worldwide reported. This paper presents an overview of the findings that scientists have realized so far. In this study articles indexed in Embase, Elsevier, PubMed, Google Scholar and using keywords SARS-CoV-2, COVID-19, Coronavirus 2019 and nCoV-2019 were used. The World Health Organization and the Centers for Disease Control and Prevention used the world's most reputable websites to obtain the latest COVID-19 disease statistics. In the initial search, 500 articles were extracted and 55 articles were selected after duplication and evaluation of title and abstract. The results show that the mortality rate of the virus in the elderly and people with underlying diseases is significantly higher than in the healthy ones. High-risk groups for the disease include cardiovascular disease, diabetes, chronic respiratory disease, and hypertension, respectively. The novel coronavirus pandemic is more widespread in humans compared to previous coronaviruses, which indicates the extremely high prevalence of the virus. No vaccine or cure has been found for the virus so far, but supportive treatments and early diagnosis are effective in the treatment process, and there are many treatments around the world for the treatment of COVID-19.
Type of Study: Review Article |
Subject:
Medical Virology
Received: 2020/03/5 | Accepted: 2020/04/15 | ePublished: 2020/05/20
Received: 2020/03/5 | Accepted: 2020/04/15 | ePublished: 2020/05/20
References
1. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020 Mar 9. [DOI:10.1101/2020.02.19.956581]
2. Müller MA, Paweska JT, Leman PA, Drosten C, Grywna K, Kemp A, Braack L, Sonnenberg K, Niedrig M, Swanepoel R. Coronavirus antibodies in African bat species. Emerging infectious diseases. 2007 Sep;13(9):1367. [DOI:10.3201/eid1309.070342] [PMID] [PMCID]
3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-3. [DOI:10.1038/s41586-020-2012-7] [PMID] [PMCID]
4. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, Duan Y, Zhang H, Wang Y, Qian Z, Cui J. On the origin and continuing evolution of SARS-CoV-2. National Science Review. 2020 Mar. [DOI:10.1093/nsr/nwaa036] [PMCID]
5. Chowell G, Abdirizak F, Lee S, Lee J, Jung E, Nishiura H, Viboud C. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC medicine. 2015 Dec;13(1):210. [DOI:10.1186/s12916-015-0450-0] [PMID] [PMCID]
6. Chowell G, Blumberg S, Simonsen L, Miller MA, Viboud C. Synthesizing data and models for the spread of MERS-CoV, 2013: key role of index cases and hospital transmission. Epidemics. 2014 Dec 1;9:40-51. [DOI:10.1016/j.epidem.2014.09.011] [PMID] [PMCID]
7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020 Jan 24. [DOI:10.1056/NEJMoa2001017] [PMID] [PMCID]
8. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020 Feb 13:200370. [DOI:10.1148/radiol.2020200370] [PMID] [PMCID]
9. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?. International journal of epidemiology. 2020 Feb 22. [DOI:10.1093/ije/dyaa033] [PMID] [PMCID]
10. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020 Feb;12(2):135. [DOI:10.3390/v12020135] [PMID] [PMCID]
11. Tavakoli A, Vahdat K, Keshavarz M. Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century. ISMJ. 2020 Jan 10;22(6):432-50. [DOI:10.29252/ismj.22.6.432]
12. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know. American journal of obstetrics and gynecology. 2020 Feb 24. [DOI:10.1016/j.ajog.2020.02.017] [PMID] [PMCID]
13. Nguyen TM, Zhang Y, Pandolfi PP. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Res. 2020 30, 189-190. [DOI:10.1038/s41422-020-0290-0] [PMID] [PMCID]
14. https://fa.wikipedia.org/wiki/
15. Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ. Nidovirales: evolving the largest RNA virus genome. Virus research. 2006 Apr 1;117(1):17-37. [DOI:10.1016/j.virusres.2006.01.017] [PMID] [PMCID]
16. Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, Zhu J, Zhang Q, Wu J, Liu L. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2. Journal of medical virology. 2020 Feb 26. [DOI:10.1002/jmv.25726] [PMID] [PMCID]
17. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020 Mar 9. [DOI:10.1101/2020.02.19.956581]
18. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, Duan Y, Zhang H, Wang Y, Qian Z, Cui J. On the origin and continuing evolution of SARS-CoV-2. National Science Review. 2020 Mar. [DOI:10.1093/nsr/nwaa036] [PMCID]
19. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nature Medicine. 2020 Mar 17:1-3. [DOI:10.1038/s41591-020-0820-9] [PMID] [PMCID]
20. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell host & microbe. 2020 Feb 7. [DOI:10.1016/j.chom.2020.02.001] [PMID] [PMCID]
21. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019 Jan;11(1):59. [DOI:10.3390/v11010059] [PMID] [PMCID]
22. Li F. Structure, function, and evolution of coronavirus spike proteins. Annual review of virology. 2016 Sep 29;3:237-61. [DOI:10.1146/annurev-virology-110615-042301] [PMID] [PMCID]
23. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B, Zhang W, Peng C, Zhang YJ. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013 Nov;503(7477):535-8. [DOI:10.1038/nature12711] [PMID] [PMCID]
24. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, Thomas WD, Thackray LB, Young MD, Mason RJ, Ambrosino DM. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proceedings of the National Academy of Sciences. 2004 Nov 2;101(44):15748-53. [DOI:10.1073/pnas.0403812101] [PMID] [PMCID]
25. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International journal of antimicrobial agents. 2020 Feb 17:105924. [DOI:10.1016/j.ijantimicag.2020.105924] [PMID] [PMCID]
26. Lam TT, Shum MH, Zhu HC, Tong YG, Ni XB, Liao YS, Wei W, Cheung WY, Li WJ, Li LF, Leung GM. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. BioRxiv. 2020 Jan 1. [DOI:10.1101/2020.02.13.945485]
27. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020 Feb 22;395(10224):565-74. [DOI:10.1016/S0140-6736(20)30251-8]
28. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Current Biology. 2020 Mar 19. [DOI:10.1016/j.cub.2020.03.063] [PMID] [PMCID]
29. Adams JG, Walls RM. Supporting the health care workforce during the COVID-19 global epidemic. JAMA. 2020 Mar 12. [DOI:10.1001/jama.2020.3972] [PMID]
30. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID‐19 infection: Different points from adults. Pediatric pulmonology. 2020 Mar 5. [DOI:10.1002/ppul.24718] [PMID] [PMCID]
31. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2020 Jan 1. [DOI:10.1101/2020.02.06.20020974]
32. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020 Mar 13:1-6. [DOI:10.1007/s12098-020-03263-6] [PMID] [PMCID]
33. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020 Feb 15;395(10223):507-13. [DOI:10.1016/S0140-6736(20)30211-7]
34. Coronavirus Outbreak. Available at: https://www.worldometers. info/coronavirus/. Accessed 23 Feb 2020.
35. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Bmj. 2020 Feb 19;368. [DOI:10.1136/bmj.m606] [PMID] [PMCID]
36. World Health Organization. Situation reports. Available at: https://www.who.int /emergencies/diseases/novel-coronavirus-2019/ situation-reports/. Accessed 22 Feb 2020.
37. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020 Feb 18:1-9. [DOI:10.20944/preprints202001.0381.v1]
38. Chen F, Liu ZS, Zhang FR, Xiong RH, Chen Y, Cheng XF, Wang WY, Ren J. Frist case of severe childhood novel coronavirus pneumonia in China. Zhonghua er ke za zhi= Chinese journal of pediatrics. 2020 Feb 11;58:E005.
39. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. First case of neonate infected with novel coronavirus pneumonia in China. Zhonghua er ke za zhi= Chinese journal of pediatrics. 2020 Feb 17;58: E009.
40. Zhao J, Yang Y, Huang HP, Li D, Gu DF, Lu XF, Zhang Z, Liu L, Liu T, Liu YK, He YJ. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. medRxiv. 2020 Jan 1. [DOI:10.1101/2020.03.11.20031096]
41. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, Zhou P. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerging microbes & infections. 2020 Jan 1;9(1):386-9. [DOI:10.1080/22221751.2020.1729071] [PMID] [PMCID]
42. Wu YC, Chen CS, Chan YJ. Overview of the 2019 novel coronavirus (2019-nCoV): The pathogen of severe specific contagious pneumonia (SSCP). J Chin Med Assoc. 2020 Feb 11.
43. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020 Feb 19:200432. [DOI:10.1148/radiol.2020200432] [PMID] [PMCID]
44. McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate. Hirsch MS, Bloom A (Eds.). Accessed Mar. 2020;5.
45. Johns Hopkins Center for Health Security. COVID-19. Johns Hopkins University; 2020. Available from: http://www.centerforhealthsecurity.org/resources/COVID-19/
46. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-3. [DOI:10.1038/s41586-020-2012-7] [PMID] [PMCID]
47. Farnoosh G, Alishiri G, Hosseini Zijoud SR, Dorostkar R, Jalali Farahani A. Understanding the 2019-novel Coronavirus (2019-nCoV) and Coronavirus Disease (COVID-19) Based on Available Evidence-A Narrative Review. Journal of Military Medicine. 2020 Jan;22(1):1-1.
48. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020 Mar;30(3):269-71. [DOI:10.1038/s41422-020-0282-0] [PMID] [PMCID]
49. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends. 2020 Feb 29;14(1):69-71. [DOI:10.5582/bst.2020.01020] [PMID]
50. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine. 2020 Jan 31. [DOI:10.1056/NEJMoa2001191] [PMID] [PMCID]
51. Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?. International Journal of Antimicrobial Agents. 2020 Mar 13:105944. [DOI:10.1016/j.ijantimicag.2020.105944] [PMID] [PMCID]
52. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Zhang J, Yin P. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020 Jan 1. [DOI:10.1101/2020.03.17.20037432]
53. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases. 2020 Apr 1;20(4):398-400. [DOI:10.1016/S1473-3099(20)30141-9]
54. Monteil V , Kwon H , Prado P , Hagelkrüys A , Wimmer R, Stahl M et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell press 2020 Apr 3. DOI: 10.1016/j.cell.2020.04.004 [DOI:10.1016/j.cell.2020.04.004] [PMID] [PMCID]
55. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. 2020 Feb 29;395(10225):689-97 [DOI:10.1016/S0140-6736(20)30260-9]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |